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Background: miR-126 plays an important role in the proliferation, invasion, migration, and chemotherapeutics
resistance in cancer. Epigallocatechin-3-gallate (EGCG), as the major polyphenolic constituent present in green tea,
is a promising anticancer agent. However, the role of miR-126 in EGCG anticancer remains unclear. Here, we investigated
the effects of miR-126 and EGCG on cell viability, apoptosis, cell cycle distribution of osteosarcoma cells and the
sensitization of miR-126 on osteosarcoma cells to EGCG.
Methods: The cell viability, apoptosis and cycle distribution were analyzed using MTT assay and flow cytometry.
Results: Our results showed that EGCG (0.025, 0.05, 0.1, 0.2 g/L) suppresses proliferation of osteosarcoma MG63
and U2OS cells in a concentration-dependent and time-dependent manner and the inhibitory effects of 0.05 g/L
EGCG on U2OS cells were roughly equivalent to 20 μM cisplatin (DDP); miR-126 could promote apoptosis and
inhibit proliferation in U2OS cells but without significant effects on cell cycle G1 phase arrest; EGCG suppressed
proliferation of U2OS cells through induction of cell cycle G1 arrest and apoptotic death; overexpression of miR-126
enhanced the inhibitory effects of EGCG on proliferation in U2OS cells via promotion of apoptosis.
Conclusions: Our results demonstrate that enhanced expression of miR-126 increased the sensitivity of osteosarcoma
cells to EGCG through induction of apoptosis.
Keywords: Osteosarcoma, miR-126, Epigallocatechin-3-gallate, Sensitization, ApoptosisBackground
Osteosarcoma is a primary malignant bone tumor with
high morbidity that occurs mainly in children and adoles-
cents. Multiple options for the treatment of osteosarcoma
have been described, including chemotherapy, radiation,
and so on, however, therapeutic efficacy is typically transi-
ent and mostly absent with advanced disease [1]. Therefore,
the need for more rational approaches to osteosarcoma
therapy is essential.
Epigallocatechin-3-gallate (EGCG) is the most abundant
catechin in green tea, showing anti-inflammatory, antioxi-
dant, anticancer and immunomodulatory activities [2-5].
It has been shown that EGCG has extensive anticancer ac-
tivities, including in breast cancer [6], cervical cancer [7],* Correspondence: hexj2014@126.com
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unless otherwise stated.lung cancer [8], prostate cancer [9], colon cancer [10],
head and neck cancer [11], gastric cancer [12], ovarian
cancer [13], even cancer stem cells [14], and so on. It was
reported that combined administration of EGCG and
interleukin 1 (IL-1) receptor antagonist could efficiently
decrease IL-1-induced tumorigenic factors, leading to
reduction in angiogenesis and invasiveness in human
osteosarcoma cells [15]. It suggests that a combination
of EGCG and interfering approaches against factors that
play a crucial role in tumor progression is a promising
strategy for improving therapeutic efficacy, including
osteosarcoma.
MicroRNAs (miRs), a class of 22-nucleotide noncoding
RNAs, have emerged as critical components of gene-
regulatory networks controlling numerous important
pathophysiological processes, including the initiation
and progression of tumors. Studies on miRs have opened
new avenues for both the diagnosis and treatment ofhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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found to be involved in the proliferation, invasion, migra-
tion, and drug resistance [20] in osteosarcoma cells. It was
found that miR-126 was consistently underexpressed in
osteosarcoma tissues and cell lines and functioned as a
tumor suppressor in osteosarcoma [19]. Studies showed
that miR-126 could enhance the sensitivity of lung cancer
[21] and cervical cancer [22] cells to anticancer agents.
However, whether miR-126 can sensitize osteosarcoma
cells to EGCG remains to be elucidated.
In this study, the effects of miR-126 and EGCG on the
proliferation, apoptosis and cell cycle in osteosarcoma
cells were investigated. Our results showed that miR-126
could enhance the sensitivity of osteosarcoma U2OS cells
to EGCG, providing novel approaches or targets for redu-
cing drug resistance in cancer.Methods
Cell culture and stimulation
MG63 and U2OS cell lines (American Type Culture Col-
lection (ATCC), USA) were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) culture medium at 5% CO2.
Cells were treated with EGCG (0.025, 0.05, 0.1, 0.2 g/L)
for 24, 48 and 72 hours, or EGCG (0.05 g/L), cisplatin
(DDP, 20 μM) or rapamycin (RAPA, 100 nm) for 48 hours
as indicated. To investigate the roles of miR-126 in U2OS
cells, the lentiviral vectors comprising pre-miR-126 or
anti-miR-126 were constructed and used to infect U2OS
cells, establishing stable U2OS cell lines overexpressing or
silencing miR-126.Cell proliferation assay
Cells treated with indicated reagents or samples in expo-
nential growth were plated at a final concentration of
2 × 103 cells per well in 96-well plates. The viability of
cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay after 24, 48
and 72 hours of seeding. The optical density at 570 nm
(OD570) of each well was measured with an enzyme-
linked immunosorbent assay (ELISA) reader (ELX-800
type, BioTek Winooski, VT, USA).Cell apoptosis assay
After being incubated in the presence of EGCG or RAPA
for 48 hours, cells were harvested and treated with fluores-
cein isothiocyanate (FITC, BioVision, Mountain View, CA,
USA) according to the manufacturer’s instructions. Cell
apoptosis was detected by analyzing Annexin V-FITC
binding by flow cytometry (Ex = 488 nm; Em = 530 nm)
using a FITC signal detector and a propidium iodide
(PI) signal detector.Cell cycle analysis
The cells were digested with trypsin (Auragene Bioscience
Corporation, Changsha, China) and collected after treat-
ment for 48 hours, and washed with phosphate-buffered
saline (PBS) twice. The cells were resuspended in PBS
and then fixed in 70% ethanol at 4°C for 18 hours. The
cells were washed with PBS and resuspended in Staining
Solution (50 μg/mL of PI, 1 mg/mL of RNase A, 0.1%
Triton X-100 in PBS). The stained cells (1 × 105) were then
analyzed with a flow cytometer (Beckman Coulter, Brea,
CA, USA).Statistical analysis
Data were expressed as mean ± standard deviation (SD)
from at least three separate experiments. Statistical ana-
lysis was carried out using SPSS 15.0 software (SPSS Inc,
Chicago, IL, USA). The difference between two groups was
analyzed by the Student’s t test. A value of P <0.05 was
considered statistically significant.Results
EGCG inhibits proliferation of osteosarcoma cells
To investigate the effects of EGCG on proliferation of
osteosarcoma cells, the human osteosarcoma U2OS and
MG63 cells were treated with different concentrations
(0.025, 0.05, 0.1, 0.2 g/L) of EGCG for 24, 48, or 72 hours,
respectively. The MTT results showed that the relative in-
hibitory rate of EGCG on U2OS and MG63 cells increased
with enhancement of its treatment concentration and
time. It suggests that EGCG suppresses proliferation of
osteosarcoma cells in a concentration-dependent and
time-dependent manner.Overexpression of miR-126 augments EGCG inhibiting
proliferation of osteosarcoma cells
As showed in Figure 1C, overexpression of miR-126 de-
creased cell viability in U2OS cells, indicating that miR-126
serves as a suppressor in osteosarcoma cells. Moreover,
RAPA, as the inhibitor of the mammalian target of rapamy-
cin (mTOR) pathway, could not affect miR-126 inhibition
of proliferation of U2OS cells, suggesting that the role of
miR-126 in osteosarcoma is not dependent on the mTOR
pathway.
MTT assay showed that both DDP and EGCG could
significantly inhibit the proliferation of osteosarcoma
U2OS cells. The inhibitory effects of 0.05 g/L EGCG on
U2OS cells were roughly equivalent to 20 μM DDP. More-
over, overexpression of miR-126 significantly decreased
cell viability in U2OS cells treated with ECGC compared
with ECGC treatment alone or combination of inhibition
of miR-126 and ECGC treatment (Figure 1C).
Figure 1 Effect of EGCG and miR-126 on proliferation in osteosarcoma cells. The relative inhibitory rate of EGCG on osteosarcoma MG63
(A) and U2OS (B) cells (C) The cell viability in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG at indicated
concentration. *P <0.05 vs. indicated group; aP <0.05 vs. Con alone group; bP <0.05 vs. anti-miR-126 alone group; cP <0.05 vs. pre-miR-126 alone
group. Con, control; DDP, cisplatin; EGCG, epigallocatechin-3-gallate; miR, microRNA; RAPA, rapamycin.
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apoptosis in osteosarcoma cells
Flow cytometry results showed that overexpression of
miR-126 could increase the apoptotic rate of osteosar-
coma U2OS cells. Inhibition of miR-126 could decrease
the apoptotic rate of osteosarcoma U2OS cells. The
apoptosis in osteosarcoma U2OS cells induced by EGCG
(0.05 g/L) was higher than that in control or overexpres-
sion of miR-126 alone group. Overexpression of miR-
126 significantly enhanced EGCG-induced apoptosis inosteosarcoma U2OS cells and inhibition of miR-126 re-
duced EGCG-induced apoptosis in osteosarcoma U2OS
cells (Figure 2).
To investigate whether the mTOR pathway is involved
in miR-126 regulation of apoptosis in osteosarcoma U2OS
cells, its inhibitor RAPA was used. The results showed
that RAPA could not affect the apoptotic rate induced by
miR-126 in U2OS cells, suggesting that the mTOR path-
way is not involved in miR-126 promotion of apoptosis in
osteosarcoma U2OS cells (Figure 2).
Figure 2 Effect of EGCG and miR-126 on apoptosis in osteosarcoma cells. (A) The representative images of flow cytometry analysis using
Annexin V and PI staining. (B) The apoptotic rate in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG.
*P <0.05 vs. indicated group; aP <0.05 vs. Con alone group; bP <0.05 vs. anti-miR-126 alone group; cP <0.05 vs. pre-miR-126 alone group. Con,
control; DDP, cisplatin; EGCG, epigallocatechin-3-gallate; miR, microRNA; PI, propidium iodide; RAPA, rapamycin.
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As showed in Figure 3, overexpression of miR-126 or in-
hibition of miR-126 by anti-miR-126 did not have marked
effects on the cell cycle G1 phase proportion in U2OS
cells. And EGCG significantly increased the G1 proportion
in U2OS cells and this action was not interfered by over-
expression of miR-126 or inhibition of miR-126. Moreover,the ratios of G1 to S in U2OS cells were 2.8 in control, 4.8
in the pre-miR-126 group, 2.2 in the anti-miR-126 group,
26.2 in the EGCG group, 32.8 in the pre-miR-126 + EGCG
group, and 32.0 in the anti-miR-126 + EGCG group. These
data suggest EGCG may suppress G1/S transition in
osteosarcoma cells, resulting in cell cycle G1 phase arrest,
and this process is not affected by miR-126. In addition,
Figure 3 Effect of EGCG and miR-126 on cell cycle in osteosarcoma cells. (A) The representative images of flow cytometry analysis using PI
staining. (B) The cell cycle distribution in U2OS cells infected with anti-miR-126, pre-miR-126, or treated with RAPA, DDP or EGCG. *P <0.05 vs. indicated
group; aP <0.05 vs. Con alone group; bP <0.05 vs. anti-miR-126 alone group; cP <0.05 vs. pre-miR-126 alone group. Con, control; DDP, cisplatin; EGCG,
epigallocatechin-3-gallate; miR, microRNA; PI, propidium iodide; RAPA, rapamycin.
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miR-126 or anti-miR-126 did not affect the cell cycle G1
phase proportion in U2OS cells.
Discussion
The natural product EGCG is the major polyphenolic con-
stituent found in green tea. Studies suggest that EGCG is
related to the potential health benefits attributed to green
tea consumption [23]. The anticancer activity of EGCG
has been extensively explored in past years. Although it is
demonstrated that EGCG can suppress proliferation of
various tumor cells, to our knowledge, articles about the
roles of EGCG in osteosarcoma are few. In the presentstudy, we confirm that EGCG can suppress proliferation of
osteosarcoma MG63 and U2OS cells in a concentration-
dependent and time-dependent manner; and the inhibitory
effects of 0.05 g/L EGCG on U2OS cells were roughly
equivalent to 20 μM DDP. These results provide novel evi-
dence supporting development of EGCG for prevention of
cancer, especially osteosarcoma.
It is well known that dysregulation of miRs will pro-
mote the malignant progression of tumor. Emerging evi-
dences show that miRs also play an important role in the
chemoresistance of cancer [24] and interference of some
crucial miRs will improve the therapeutic efficacy of che-
motherapeutics [25]. miR-126 is a commonly discovered
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proliferation, invasion, and migration in tumors [21,22,26].
Here, we also found miR-126 was underexpressed in
MG63 and U2OS cells (data not shown), consistent with
the results obtained by Yang et al. [19]; in the report, it was
discovered that a low level of miR-126 was expressed in
osteosarcoma tissues and cell lines. In addition, we found
that overexpression of miR-126 resulted in inhibition of
proliferation and induction of apoptosis in osteosarcoma
U2OS cells. These results further confirm that miR-126
acts as a tumor suppressor in osteosarcoma.
Studies showed that miR-126 could enhance the sensi-
tivity of non-small-cell lung cancer to adriamycin and
vincristine [21] and cervical cancer cells to bleomycin [22].
In our study, we found that overexpression of miR-126
could enhance the sensitivity of osteosarcoma U2OS cells
to polyphenolic EGCG. Our results showed that overex-
pression of miR-126 significantly enhanced the inhibitory
action of EGCG on U2OS cells. Subsequently, we further
verified that miR-126 could promote EGCG-induced apop-
tosis in U2OS cells; and EGCG-induced G1 phase arrest in
U2OS cells was not apparently affected by miR-126 levels
due to miR-126 itself having no marked effects on the G1
phase proportion in U2OS. The role of miR-126 identified
by us in osteosarcoma cells is consistent with its perform-
ance in gastric cancer cells, that miR-126 could induce its
apoptotic death but had no effects on cell cycle [27]. It sug-
gests that the mechanisms underlying EGCG suppressing
the proliferation of osteosarcoma cells mainly involve its
ability to induce apoptosis and cell cycle arrest in the G1
phase, and miR-126 sensitizes U2OS cells to EGCG mainly
through promotion of apoptosis.
EGCG can protect against cancer by causing cell cycle
arrest and inducing apoptosis [28]. It was found that
EGCG could irreversibly induce cell cycle G1 phase
arrest, ultimately leading to apoptotic cell death by up-
regulation of WAF1/p21, KIP1/p27, INK4a/p16, and
INK4c/p18, and downregulation of cyclin D1, cyclin E,
cdk2, cdk4, and cdk6, irrespective of p53 status, in pros-
tate carcinoma cells [29]. Slightly unlike this, in leukemia
cells, it was demonstrated that EGCG could increase the
pre-G1 phase proportion and induce apoptosis by upregu-
lation of p53, Bax and p21 and downregulation of Bcl-
2alpha [30]. These protein molecules are potential targets
of EGCG in osteosarcoma cells. And miR-126 is likely a
promotor of apoptotic cell death in osteosarcoma cells by
regulation of PLK2, PI3KR2, Crk [27], PI3K, Akt [31], and
so on.
Our results illustrate the effects of miR-126 and EGCG
on proliferation, apoptosis and cell cycle distribution.
However, further studies are required to elucidate the
specific molecular mechanisms underlying miR-126 promo-
tion of EGCG-induced apoptosis in osteosarcoma U2OS
cells.Conclusions
In summary, miR-126 can enhance EGCG suppressing
the proliferation of osteosarcoma cells through induction
of apoptosis.
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